Skip to main content
OpenTrials
Completed

NCT Number: NCT05938283

Pilot Study of Hypertrophic Cardiomyopathy & Implantable Cardioverter Defibrillator Assessment: (Subcutaneous vs Transvenous)

Pilot randomised trial to assess recruitment for a larger trial to compare the efficacy and adverse effects of the subcutaneous and transvenous ICD in patients with hypertrophic cardiomyopathy (HCM) and indication for ICD therapy, with no requirement for pacing

Completed

Looking for future studies?

Notify Me

Key information

About this study

This study aims to test the feasibility of conducting a trial to investigate the use of subcutaneous implantable defibrillator (SICD) in patients with hypertrophic cardiomyopathy (HCM) and to determine whether SICD produces more complications than conventional, transvenous implantable defibrillator (TV ICD).

The primary analysis for the main trial is designed to test whether the S-ICD is non-inferior to the TV-ICD with respect to the primary endpoint of inappropriate shock treatment and complications. For the incidence of the primary endpoint statistical significance and 99% confidence intervals are calculated using Cox' proportional hazards model. Non-inferiority is considered to be established if the upper boundary of the one-sided 99% confidence interval did not exceed 1.92 (absolute difference < 12%).

Participant duration is expected to be 14 months. (12 months follow up post device implant) Recruitment duration expected to be 6-10 months.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Hypertrophic Cardiomyopathy and a referred for ICD therapy with no pacing requirement.

Exclusion criteria

  • Patients with sustained ventricular tachycardia less than 170 bpm
  • Patients having an indication for pacing therapy. E.g. sick sinus syndrome.
  • Patients failing appropriate QRS/T-wave sensing with the automated S-ICD ECG automated patient screening provided by Boston Scientific
  • A minimum of 1 sensing vector passing in supine, standing.
  • Patients with incessant ventricular tachycardia
  • Patients who have had a previous ICD implant
  • Patient who receives cardiac contractility modulation therapy or are likely to receive cardiac contractility modulation therapy
  • Patients with a serious known concomitant disease with a life expectancy of less than one year
  • Patients with circumstances that prevent follow-up (no permanent home or address, transient, etc.)
  • Patients who are unable to give informed consent
  • Patients who are not suitable for TV-ICD implantation, according to the discretion of the physician, are not screened for enrolment (SVC occlusion).

Treatment and study plan

Implantable Cardioverter Defibrillator implant

Device

ICD implant to protect patients from life threatening ventricular tachycardia or ventricular fibrillation

Primary outcomes

  1. Rate of recruitment

    Time frame: through study completion, expected at 10 months to 1 year

    Assessment of rate of recruitment per month

  2. Composite of inappropriate shock and ICD related complications

    Time frame: 12 months

    Rate of inappropriate shocks and ICD related complications across the patients over a 12 month period.

Secondary outcomes

  1. All- cause mortality

    Time frame: 12 months

    % of patients who die

  2. MACE events

    Time frame: 12 months

    Major Adverse Cardiac Event (MACE), defined as cardiac death, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting and/or any valve surgery.

  3. Appropriate shocks and patients with appropriate shocks

    Time frame: 12 months

    Rate over 12 months determined by IBHRE accredited Cardiac Scientist

  4. Inappropriate shocks and patients with inappropriate shocks

    Time frame: 12 months

    Rate over 12 months determined by IBHRE accredited Cardiac Scientist

  5. Complications

    Time frame: 12 months

    individually, defined as infections, bleedings, thrombotic events, pneumothorax, perforation/tamponade, lead reposition and lead- or device failures

  6. Cardiac decompensation

    Time frame: 12 months

    Measured by admissions for Heart failure or unplanned outpatient appointments.

  7. Crossovers to the other arm

    Time frame: 12 months

    Amount of patients moving from SICD to TV group and visa versa over 12 month period.

  8. Appropriate shock treatment in ATP or monitor zone

    Time frame: 12 months

    Rate over 12 months determined by IBHRE accredited Cardiac Scientist

  9. Quality of life assessed by SF-36 survey

    Time frame: 12 months

    Scores for the different domains are converted and pooled using a scoring key, for a total score indicating a range of low to high QOL.

  10. Quality of life assessed by EQ5D survey

    Time frame: 12 months

    Scores for the different domains are converted and pooled using a scoring key, for a total score indicating a range of low to high QOL.

  11. Cardiac (pre-) syncope events

    Time frame: 12 months

    rate of patients with these events over a 12 month period

  12. Time to successful therapy

    Time frame: 12 months

    Time in months or days from implant to date of succesful therapy

  13. First shock conversion efficacy

    Time frame: 12 months

    % of first shocks that cardiovert ventricular arrhythmia

  14. Implant procedure time

    Time frame: Procedure duration- average of 2 hours expected

    Duration of implant from needle to skin to skin closure.

  15. Hospitalization rate

    Time frame: 12 months

    Rate of patient hospitalisation for cardiac and non-cardiac causes over a 12 month period.

  16. Fluoroscopy time

    Time frame: Procedure duration- average of 2 hours expected

    Amount of fluoroscopy required to complete implant procedure, expected fluoroscopy time of approximately 1 minute per patient.

Other outcomes

  1. Drop out rate

    Time frame: 12 months

    % of patients that do not complete the sudy

  2. Data Quality

    Time frame: 12 months

    % of data completed

  3. Eligibility of SICD

    Time frame: 12 months

    % Of patients referred for recruitment was SICD screening making patients illegible. Either Yes or no.

Sponsors and collaborators

Lead sponsor

Barts & The London NHS Trust

Other

Collaborators

  • Boston Scientific Corporation
  • Queen Mary University of London

Registry information

Acronym: HICD

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Jul 10, 2023
Registry last updated
Feb 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.